資料來源：

[1] Anavex Life Sciences Corp,US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome, Nov 7, 2022; https://www.biospace.com

[2] Gantois I., Khoutorsky A., Popic J., et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat. Med. 2017;23(6):

674–677.

[3] Winarni T.I., Schneider A., Borodyanskara M., Hagerman R.J. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Rep. Genet. 2012;2012:280813

[4] Zynerba.Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel (CBD Gel) in Fragile X Syndrome. Retrieved July 6, 2022 from https://www.zynerba.com

[5] Tetra Therapeutics,Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome, July 12, 2022;

https://www.businesswire.com